CART-ddBCMA is under clinical development by Arcellx and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData, Phase II drugs for Relapsed Multiple Myeloma have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CART-ddBCMA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CART-ddBCMA overview

Gene therapy is under development for the treatment of relapsed and refractory multiple myeloma. The immune cell therapy consists of Antigen Receptor Complex T cells (ARC-T) that kills the tumor cells. It acts by targeting cells expressing BCMA. It is administered through intravenous route.

Arcellx overview

Arcellx is a biopharmaceutical company which develops, manufactures and markets novel and adaptive cell therapies for the treatment of cancer, acute myeloid leukemia, solid tumors and autoimmune diseases. Arcellx is headquartered in Gaithersburg, Maryland, the US.

For a complete picture of CART-ddBCMA’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.